Tutti gli studi
ReclutamentoFase II e Fase III (Integrata)Interventistico

AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-102 TREATMENT ON DISEASE PROGRESSION PRIOR TO HUMAN STEM CELL TRANSPLANT (HSCT)

Cerebral X-linked adrenoleukodystrophy (CALD) is a rare genetic condition affecting males. It damages myelin, the protective covering around nerves in the brain. Over time, this causes trouble with walking, talking, seeing, and hearing. A stem cell transplant can help, but finding a match and preparing for the procedure takes time. This study tests a new medicine called MIN-102. Researchers want to find out whether taking MIN-102 can stabilise or pause the disease while patients wait for a transplant. Because this is an open-label study, all participants receive the study medicine. Doctors will track health changes through regular clinic visits, physical checks, and brain MRI scans. The main goal is to find out if MIN-102 can protect brain function and stop symptoms from getting worse during this critical period.

A colpo d'occhio

Stato
Reclutamento
Fase
Fase II e Fase III (Integrata)
Sponsor
Minoryx Therapeutics S.L.
Obiettivo di iscrizione
16
Inizio
21 giu 2024

Di cosa tratta questo studio?

Cerebral X-linked adrenoleukodystrophy (often shortened to CALD) is a rare inherited condition that mainly affects boys and men. In CALD, the body cannot break down certain fatty substances properly. These fats build up and cause inflammation that strips away the protective coating around nerve cells in the brain. Without this protection, nerve signals slow down, leading to rapid changes in movement, eyesight, speech, and behaviour.

Currently, the main treatment to stop CALD from progressing is a human stem cell transplant. This treatment replaces damaged blood-forming cells with healthy donor cells. However, preparing for a transplant takes time. During this waiting period, the disease can continue to advance, which can lead to permanent nerve damage. Researchers hope that giving a medicine called MIN-102 can act as a shield to help calm brain inflammation and protect nerve cells before transplant surgery.

In this study, doctors want to see if MIN-102 can achieve what they call 'arrested disease'—meaning the rapid worsening of brain damage is stopped. They will monitor changes using detailed MRI scans of the brain and regular physical tests that assess everyday abilities like walking, hearing, and communicating.

Taking part helps scientists understand whether MIN-102 could become a valuable treatment to preserve brain function. Because this is an open-label trial, every participant who joins will receive the active study medicine rather than a dummy treatment (placebo).

Punti chiave

  • The study tests whether MIN-102 can halt disease progression in males with cerebral adrenoleukodystrophy (CALD).
  • It aims to protect brain cells while patients prepare for a future stem cell transplant.
  • Every participant receives the active study medication (there is no placebo).
  • Doctors will carefully monitor brain health using regular MRI scans and nerve function checks.
  • Participation is entirely voluntary and does not replace your standard NHS care options.

Chi può essere idoneo?

This trial is designed for males who have been diagnosed with cerebral adrenoleukodystrophy (CALD) and are being considered for a stem cell transplant. While the trial focuses heavily on young boys, study criteria can vary, so the trial team will confirm the exact age requirements.

To be suitable, participants must be at a stage of the condition where doctors believe pausing the disease could still protect brain function. Participants will also need to be able to have regular brain MRI scans and travel to the study centre for planned check-ups.

People may not be able to join if their condition is too advanced, if they have other serious health problems, or if they have had bad reactions to similar medicines in the past. Your specialist care team can review your medical records to see if this trial matches your situation.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Male diagnosed with cerebral X-linked adrenoleukodystrophy (CALD)
  2. Currently being evaluated or waiting for a stem cell transplant
  3. Able to attend regular hospital visits and undergo brain MRI scans
  4. No other major medical conditions that would make taking part unsafe
  5. Willing to take the study medicine as instructed by the trial team
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you or your child takes part, you will attend regular appointments at a specialised hospital clinic. During these visits, doctors will perform detailed health checks. These include neurological exams to check walking, vision, hearing, and speech. Participants will also have regular brain MRI scans to look closely at changes inside the brain.

The study involves taking the medication MIN-102 regularly as directed by the research team. The study is divided into numbered visits (up to Visit 12 and beyond) over several months to track progress before any planned stem cell transplant. The medical team will also keep in close contact to monitor overall wellbeing and check for any side effects.

Rischi e benefici potenziali

A potential benefit of joining this study is that MIN-102 may help slow down brain inflammation and pause disease symptoms before a stem cell transplant. Participants will also receive very close, expert medical monitoring throughout the trial. However, because MIN-102 is still being tested, there is no guarantee it will work, and it may cause side effects that the study team will explain in detail. Having frequent clinic visits, blood tests, and MRI scans can also take time and effort. Taking part is completely voluntary, and you are free to leave the study at any point without it affecting your standard NHS care.

Luoghi (3)

Alcune posizioni dei siti sono approssimative. Stiamo migliorando questo — si prega di verificare con il team di prova prima di viaggiare.
  • —
    Non verificato
    Germania
  • —
    Non verificato
    Francia
  • —
    Non verificato
    Spagna

Domande comuni

What is MIN-102?

MIN-102 (also known as leriglitazone) is an experimental medicine designed to reduce inflammation and protect nerve cells in the brain from damage caused by CALD.

Does this trial replace a stem cell transplant?

No. The main aim is to test whether MIN-102 can stabilise the condition and protect the brain before a patient undergoes a stem cell transplant.

Will anyone receive a placebo (dummy drug)?

No. This is an 'open-label' study, which means all participants will receive the active study medicine, MIN-102.

Are MRI scans painful?

MRI scans are painless, but they do require lying very still inside a machine that makes loud tapping noises. Earplugs or headphones are provided, and younger children may be offered gentle sedation if needed.

Can we leave the trial if we change our minds?

Yes. You can withdraw from the study at any time, for any reason. Doing so will not affect the standard medical care you or your child receives.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS …" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.